Evidence map›Paper›PMID 31469428›Full record

ArticleHepatology (Baltimore, Md.)2020

Mesencephalic Astrocyte-Derived Neurotrophic Factor Inhibits Liver Cancer Through Small Ubiquitin-Related Modifier (SUMO)ylation-Related Suppression of NF-κB/Snail Signaling Pathway and Epithelial-Mesenchymal Transition.

Jun Liu, Zhengsheng Wu, Dan Han, Chuansheng Wei, Yanyan Liang, Tongcui Jiang, Lu Chen, Manqi Sha, Yajie Cao, Fan Huang and 9 more

Open access · hybridAbstract read
In one paragraph

Article in Hepatology (Baltimore, Md.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 93 papers.

0numbers the graph read from it
0cells of the map it votes in
93citing papers in PubMed
7.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

93 citing papers in PubMed, 166 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. The role of SUMOylation in epithelial-mesenchymal transition.Journal of molecular medicine (Berlin, Germany) · 2025
    Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review

33 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 2 institutions in 2 countries.

Jun Liu *School of Basic Medical Sciences, Anhui Medical University, Hefei, China.
Zhengsheng Wu *School of Basic Medical Sciences, Anhui Medical University, Hefei, China.
Dan HanSchool of Basic Medical Sciences, Anhui Medical University, Hefei, China.
Chuansheng WeiSchool of Basic Medical Sciences, Anhui Medical University, Hefei, China.
Yanyan LiangSchool of Basic Medical Sciences, Anhui Medical University, Hefei, China.
Tongcui JiangSchool of Basic Medical Sciences, Anhui Medical University, Hefei, China.
Lu ChenBiopharmaceutical Research Institute, Anhui Medical University, Hefei, China.
Manqi ShaBiopharmaceutical Research Institute, Anhui Medical University, Hefei, China.
Yajie CaoBiopharmaceutical Research Institute, Anhui Medical University, Hefei, China.
Fan HuangThe First Affiliated Hospital of Anhui Medical University, Hefei, China.
Xiaoping GengThe First Affiliated Hospital of Anhui Medical University, Hefei, China.
Jishuang YuBiopharmaceutical Research Institute, Anhui Medical University, Hefei, China.
Yujun ShenSchool of Basic Medical Sciences, Anhui Medical University, Hefei, China.
Hua WangThe First Affiliated Hospital of Anhui Medical University, Hefei, China.ORCID 0000-0002-2605-5697
Lijie FengSchool of Basic Medical Sciences, Anhui Medical University, Hefei, China.
Dong WangSchool of Basic Medical Sciences, Anhui Medical University, Hefei, China.
Shengyun FangCenter for Biomedical Engineering and Technology, University of Maryland, Baltimore, MD.
Siying WangSchool of Basic Medical Sciences, Anhui Medical University, Hefei, China.
Yuxian ShenSchool of Basic Medical Sciences, Anhui Medical University, Hefei, China.
Anhui Medical University · CNUniversity of Maryland, Baltimore · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsEndoplasmic reticulum (ER) stress is associated with liver inflammation and hepatocellular carcinoma (HCC). However, how ER stress links inflammation and HCC remains obscure. Mesencephalic astrocyte-derived neurotrophic factor (MANF) is an ER stress-inducible secretion protein that inhibits inflammation by interacting with the key subunit of nuclear factor kappa light chain enhancer of activated B cells (NF-κB) p65. We hypothesized that MANF may play a key role in linking ER stress and inflammation in HCC. APPROACH AND

resultsHere, we found that MANF mRNA and protein levels were lower in HCC tissues versus adjacent noncancer tissues. Patients with high levels of MANF had better relapse-free survival and overall survival rates than those with low levels. MANF levels were also associated with the status of liver cirrhosis, advanced tumor-node-metastasis (TNM) stage, and tumor size. In vitro experiments revealed that MANF suppressed the migration and invasion of hepatoma cells. Hepatocyte-specific deletion of MANF accelerated N-nitrosodiethylamine (DEN)-induced HCC by up-regulating Snail1+2 levels and promoting epithelial-mesenchymal transition (EMT). MANF appeared in the nuclei and was colocalized with p65 in HCC tissues and in tumor necrosis factor alpha (TNF-α)-treated hepatoma cells. The interaction of p65 and MANF was also confirmed by coimmunoprecipitation experiments. Consistently, knockdown of MANF up-regulated NF-κB downstream target genes TNF-α, interleukin (IL)-6 and IL-1α expression in vitro and in vivo. Finally, small ubiquitin-related modifier 1 (SUMO1) promoted MANF nuclear translocation and enhanced the interaction of MANF and p65. Mutation of p65 motifs for SUMOylation abolished the interaction of p65 and MANF.

conclusionsMANF plays an important role in linking ER stress and liver inflammation by inhibiting the NF-κB/Snail signal pathway in EMT and HCC progression. Therefore, MANF may be a cancer suppressor and a potential therapeutic target for HCC.

Indexed as

Epithelial-Mesenchymal TransitionCarcinoma, HepatocellularCell Line, TumorEndoplasmic Reticulum StressHumansInflammationLiver NeoplasmsNerve Growth FactorsRecurrenceSignal TransductionSmall Ubiquitin-Related Modifier ProteinsSnail Family Transcription FactorsTranscription Factor RelATumor Necrosis Factor-alphaTumor Suppressor ProteinsMANF protein, humanNerve Growth FactorsSmall Ubiquitin-Related Modifier ProteinsSNAI1 protein, humanSnail Family Transcription FactorsTranscription Factor RelATumor Necrosis Factor-alphaTumor Suppressor Proteins

Identifiers

PMID31469428
PMCPMC7187412
OpenAlexW2970809548

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.